Alteraciones ecocardiográficas asociadas a tratamiento con trastuzumab en carcinoma mamario Her2 positivo
Cargando...
Fecha
2022
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
Antecedentes: El uso de trastuzumab se asocia con una mayor tasa de supervivencia en pacientes con cáncer de mama positivo para Her2; sin embargo, está relacionado con diferentes niveles de cardiotoxicidad que conducen a la interrupción del tratamiento, lo que puede privar a los pacientes de los beneficios de esta terapia. Objetivo: Determinar las alteraciones ecocardiográficas asociadas a tratamiento con trastuzumab en carcinoma mamario Her2 positivo. Metodología: Será un estudio observacional, analítico, de corte transversal y retrospectivo. La muestra analizada estará conformada por 78 pacientes con carcinoma mamario Her2 positivo del hospital de especialidades Teodoro Maldonado Carbo que recibieron tratamiento con trastuzumab durante el periodo del 1 de enero del 2019 al 31 de diciembre del 2019. Los datos serán tabulados en planillas de Excel y analizados en la plataforma estadística SPPS con un intervalo de confianza de 95% y un valor de significancia “p” menor a 1. Resultados esperados: El propósito de esta investigación será demostrar la presentación de alteraciones eco cardiográficas en pacientes con carcinoma mamario HER2 positivo en tratamiento con trastuzumab
Background: The use of trastuzumab is associated with a higher survival rate in patients with Her2-positive breast cancer; however, it is associated with varying levels of cardiotoxicity leading to treatment discontinuation, which may deprive patients of the benefits of this therapy. Objective: To determine the echocardiographic alterations associated with treatment with trastuzumab in Her2 positive mammary carcinoma. Methodology: It will be an observational, analytical, cross-sectional and retrospective study. The analyzed sample will be made up of 78 patients with Her2 positive breast carcinoma from the Teodoro Maldonado Carbo specialty hospital who received treatment with trastuzumab during the period from January 1, 2019 to December 31, 2019. The data will be tabulated in Excel spreadsheets and analyzed in the statistical platform SPPS with a confidence interval of 95% and a value of significance "p" less than 1. Expected results: The purpose of this research will be to demonstrate the presentation of echocardiographic alterations in patients with HER2-positive breast carcinoma in trastuzumab treatment
Background: The use of trastuzumab is associated with a higher survival rate in patients with Her2-positive breast cancer; however, it is associated with varying levels of cardiotoxicity leading to treatment discontinuation, which may deprive patients of the benefits of this therapy. Objective: To determine the echocardiographic alterations associated with treatment with trastuzumab in Her2 positive mammary carcinoma. Methodology: It will be an observational, analytical, cross-sectional and retrospective study. The analyzed sample will be made up of 78 patients with Her2 positive breast carcinoma from the Teodoro Maldonado Carbo specialty hospital who received treatment with trastuzumab during the period from January 1, 2019 to December 31, 2019. The data will be tabulated in Excel spreadsheets and analyzed in the statistical platform SPPS with a confidence interval of 95% and a value of significance "p" less than 1. Expected results: The purpose of this research will be to demonstrate the presentation of echocardiographic alterations in patients with HER2-positive breast carcinoma in trastuzumab treatment
Descripción
PDF
Palabras clave
NEOPLASIAS DE LA MAMA, ECOCARDIOGRAFIA, HOSPITAL DE ESPECIALIDADES DR. TEODORO MALDONADO CARBO, CANTON GUAYAQUIL, ECUADOR